Abstract
We analyzed 56 of 75 previously untreated patients with hepatocellular carcinoma who entered on a prospectively randomized trial of acivicin versus 4'deoxydoxorubicin (esorubicin). At least one episode of severe toxicity was documented in 23% of the patients on acivicin and 45% of those on 4'deoxydoxorubicin. Two patients responded to 4'deoxydoxorubicin. One response was partial, lasting 58 weeks, and one was complete, lasting more than 4 years. The 90% confidence interval for response is 1-20%. In view of a 45% rate of severe or worse toxicity with 4'deoxydoxorubicin, this drug cannot be recommended as treatment. There were no responses on acivicin.
Publication types
-
Clinical Trial
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Antibiotics, Antineoplastic / administration & dosage
-
Antibiotics, Antineoplastic / adverse effects
-
Antibiotics, Antineoplastic / therapeutic use*
-
Carcinoma, Hepatocellular / drug therapy*
-
Carcinoma, Hepatocellular / mortality
-
Doxorubicin / administration & dosage
-
Doxorubicin / adverse effects
-
Doxorubicin / analogs & derivatives*
-
Doxorubicin / therapeutic use
-
Drug Administration Schedule
-
Female
-
Humans
-
Isoxazoles / administration & dosage
-
Isoxazoles / adverse effects
-
Isoxazoles / therapeutic use*
-
Liver Neoplasms / drug therapy*
-
Liver Neoplasms / mortality
-
Male
-
Prospective Studies
-
Survival Rate
Substances
-
Antibiotics, Antineoplastic
-
Isoxazoles
-
Doxorubicin
-
acivicin
-
esorubicin